Latest profit margin for Astellas Pharma: 16.09% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for 4503.T is 16.09% as of September 2026. That compares with 3.11% in the prior-year period — up 417.7% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Astellas Pharma's historical trend and sector peers before judging valuation or financial health.
Over the past year, 4503.T's profit margin moved from 3.11% to 16.09% — a 417.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astellas Pharma's valuation or profitability profile.
Against Healthcare companies, 4503.T currently prints 16.09% for profit margin, while the sector average sits near 17.63%. That is roughly 8.7% below the sector mean. Large gaps often invite a closer look at Astellas Pharma's growth, margins, and balance sheet.
Profit Margin shows how effectively Astellas Pharma converts resources into returns. At 16.09%, 4503.T may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 3.11% in the prior-year period — up 417.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4503.T's profit margin (16.09%), review year-over-year change from 3.11%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.